Jennifer Nicholson, M.H.A., joined Kronos Bio in July 2020 as Vice President, Regulatory Affairs. Prior to joining Kronos Bio, she was at Acerta Pharma, a member of the AstraZeneca Group, as Head of Global Regulatory Science.  Jennifer was the Global Regulatory Lead for the Calquence (acalabrutinib) US NDA in R/R MCL which was granted accelerated approval in 2017, as well as for subsequent Calquence global filings in R/R MCL as well as CLL/SLL. Jennifer has nearly 20 years of experience in regulatory affairs, with a focus on oncology drug development for hematologic malignancies and solid tumors across all stages of development. Prior to joining Acerta, Jennifer was at Bavarian Nordic, where she focused on immuno-oncology and vaccine products as Senior Director of Regulatory Affairs. Jennifer worked as the Global Regulatory Lead on various hematology and oncology products at Jazz Pharmaceuticals, Onyx Pharmaceuticals, and Genentech, and has a proven track record of successful major filings. Jennifer received her BS in Biochemistry and Cell Biology from the University of California, San Diego, and a Masters in Health Administration (MHA) from the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.